Compare Novavax Inc (NVAX) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Royal Bank of Canada — how do they compare? Novavax Inc trades at $8.06 (market cap $1.30B), while Royal Bank of Canada trades at $210.37 (market cap $289.51B). The key difference: Royal Bank of Canada is far larger — about 222.7× Novavax Inc's market cap, and Royal Bank of Canada pays a 2.42% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | RY | |
|---|---|---|
Market Cap | $1.30B | $289.51B |
Sector | Health | Financials |
52-Week High | $11.19 | $217.87 |
52-Week Low | $6.22 | $128.46 |
Enterprise Value | $800.50M | — |
Dividend Yield | — | 2.42% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
